ArticleJournal of surgical oncology2016
Clinicopathologic and survival analysis of resected ampullary adenocarcinoma.
Article in Journal of surgical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Mixed adenoneuroendocrine carcinoma (MANEC) of the ampulla of Vater with sarcomatosis: a case report.International journal of surgery case reports · 2026Article
- Histopathologic Subtype as a Determinant of Prognosis and Chemotherapy Benefit in Resected Ampullary Adenocarcinoma.Journal of hepato-biliary-pancreatic sciences · 2026Article
- Optimizing postoperative chemotherapy for ampullary cancer: A risk-driven approach to precision care.iLIVER · 2025Article
- Adjuvant Chemotherapy Is Associated with Improved Survival in Advanced Ampullary Adenocarcinoma-A Population-Based Analysis by the German Cancer Registry Group.Journal of clinical medicine · 2025Article
- The clinical significance of the lymph node ratio as a recurrence indicator in ampullary cancer after curative pancreaticoduodenectomy.Langenbeck's archives of surgery · 2024Article
- Predicting lymph node metastasis using preoperative parameters in patients with T1 ampulla of vater cancer.BMC cancer · 2024Article
- Laparoscopic versus open pancreaticoduodenectomy: Long-term outcome from a tertiary care centre.Journal of minimal access surgery · 2024Article
- Clinicopathologic Analysis and Prognostic Factors for Survival in Patients with Operable Ampullary Carcinoma: A Multi-Institutional Retrospective Experience.Medicina (Kaunas, Lithuania) · 2024Article
- Machine learning for differentiating between pancreatobiliary-type and intestinal-type periampullary carcinomas based on CT imaging and clinical findings.Abdominal radiology (New York) · 2024Article
- Impact of circumferential resection margin on survival in ampullary cancer: retrospective analysis.BJS open · 2023Article
- Mixed adenoneuroendocrine carcinoma of the ampulla of Vater: Three case reports and a literature review.Annals of hepato-biliary-pancreatic surgery · 2023Article
- Neoadjuvant Therapy Versus Upfront Resection for Nonpancreatic Periampullary Adenocarcinoma.Annals of surgical oncology · 2023Article
- Ampulla of Vater carcinoma: advancement in the relationships between histological subtypes, molecular features, and clinical outcomes.Frontiers in oncology · 2023Review
- Development and verification of prognostic nomogram for ampullary carcinoma based on the SEER database.Frontiers in oncology · 2023Article
- Treatment Approach to Adenocarcinoma of the Ampulla of Vater.Current treatment options in oncology · 2021Review
- Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer.International journal of medical sciences · 2021Article
- Impact of lymph node staging systems in predicting outcome in patients with ampullary cancer.Annals of hepato-biliary-pancreatic surgery · 2020Article
- Mixed adenoneuroendocrine carcinoma of the ampulla of Vater: a case report and literature review.Clinical journal of gastroenterology · 2020Review
- Prognostic Nomogram for Disease-Specific Survival in Patients with Non-metastatic Ampullary Carcinoma After Surgery.Annals of surgical oncology · 2019Article
- Surgical management of periampullary adenocarcinoma: defining an optimal prognostic lymph node stratification schema.Journal of Cancer · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
introductionAmpullary adenocarcinoma (AAC) is a rare neoplasm. We sought to determine the clinicopathologic factors contributing to the overall survival (OS) and recurrence-free (RFS) survival.
methodsPatients (pts) with resected AAC were identified from 1996 to 2015 and reviewed for clinicopathologic factors and correlated with outcome.
resultsWe identified and evaluated 106 pts diagnosed with AAC. The median age was 70.2 years (range 41-86) and 60 (56.6%) were male. Overall, 105 pts (99.1%) had a pancreaticoduodenectomy. An R0 resection was achieved in 101 (95%) pts. Median follow-up was 19 months with a median OS of 49.3 months. Lymph node metastasis and poorly differentiated tumors adversely affected OS on multivariate analysis (MVA). Twenty patients (18.9%) developed recurrence. The median RFS was 27 months. RFS was adversely affected by lymph node count and metastasis, tumor differentiation, and histological subtype on MVA. Survival was not affected by the addition of adjuvant therapy. Retrieval of ≤12 lymph nodes and lymph node ratio ≥0.10 resulted in worse OS on Kaplan-Meier analysis.
conclusionsOur data show retrieval of ≤12 nodes, involvement of nodes with AAC, moderately or poorly differentiated tumors, and pancreaticobiliary subtype adversely affected survival, while the use of adjuvant therapy demonstrated no significant benefit. J. Surg. Oncol. 2016;114:170-175. © 2016 Wiley Periodicals, Inc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.